Invited Speakers from Previous Meetings

13th International Chicago Lymphoma Symposium 2016

David Weinstock, MD
Translating Scientific Discovery in T-cell Lymphoma: Current and Future States

David Scott, MBChB, PhD, FRACP, FRCPA
Integration of Diagnostic Platforms in DLBCL

Parameswaran Venugopal, MD
DLBCL in 2016: Risk Stratification based on Clinical and Biologic Features

Kieron Dunleavy, MD
Circulating Tumor DNA: Untreated Diffuse Large B-Cell Lymphoma

Lynn Wang, MD, PhD, FCAP
Ibrutinib Resistance and Implications for Clinical Practice

Elaine Jaffe, MD
The WHO classification of lymphoma: Historical Perspective and Emerging Issues

Reem Karmali, MD
No Role for Surveillance Imaging in Lymphoma (PRO)

Matt Lunning, DO
No Role for Surveillance Imaging in Lymphoma (CON)

Medhi Hamadani, MD
Beyond Matched Donors: Current Options for Allogeneic Transplantion in Lymphoma

Lindsay Morton, PhD
What Causes Lymphoma: What Should We Tell Our Patients

Youn Kim, MD
Emerging Targets, New Agents, and Improved Therapeutic Strategies in Cutaneous T-cell Lymphoma

Barbara Pro, MD
Peripheral T-Cell Lymphomas: Initial Treatment

Michele Ghielmini, MD, PhD
The Evolution Towards Non-Chemotherapeutic Approaches for Indolent Lymphomas: Pitfalls and Lessons Learned

Ann LaCasce, MD
Early Stage Hodgkin Lymphoma in 2016: Taking Stock of the Evidence

Craig Moskowitz, MD
The Status of Second-Line Thearpy in Hodgkin Lymphoma in the Near Future

Andrew Evens, DO, MSc
Management of Special Populations in Hodgkin Lymphoma

12th International Chicago Lymphoma Symposium 2015

Mary Gospodarowicz, MD
Late Effects of HL Treatment: Are We Doing Any Better?

Owen O’Connor, MD, PhD
Beyond BCR Signaling: New Targets and Therapeutic Approaches in Lymphoma

Eduardo Sotomayor, MD
The Clinical Impact of Mantle Cell Lymphoma Biology

Catherine Bollard, MD
Next Steps in the Development and Application of CAR T-Cell Therapy

Justin Kline, MD
Immunology for the Lymphoma Clinician: How T-Cells and B-Cells Interact

Margaret Shipp, MD
The Translational Path of PD-1 Therapy in Lymphoma

Mitchell Smith, MD, PhD
Chemotherapy Should Be Part of Treatment for High Tumor Burden Follicular Lymphoma (PRO)

Sonali M. Smith, MD
Chemotherapy Should Be Part of Treatment for High Tumor Burden Follicular Lymphoma (CON)

Timothy Fenske, MD
Autologous SCT Should Be a Treatment Option for Relapsed Mantle Cell Lymphoma (PRO)

Patrick Stiff, MD
Autologous SCT Should Be a Treatment Option for Relapsed Mantle Cell Lymphoma (CON)

Nancy Bartlett, MD
Response Adapted Therapy in Hodgkin Lymphoma: How Should It Be Integrated for the Treatment of Patients

Richard R. Furman, MD
Molecular Prognostication of CLL in the Era of Novel Therapeutics

Michael Hallek, MD
Optimal Therapeutic Strategies for Patients with CLL in the Current Era

Jane N. Winter, MD
Prognostication of DLBCL in the Modern Era

Jeremy S. Abramson, MD. MMSc
The Definition and Most Optimal Treatment of High Risk DLBCL

11th International Chicago Lymphoma Symposium 2014

James L. LaBelle, MD, PhD
Targeting Apoptosis in Lymphomas

Leo I. Gordon MD, FACP
Applications of Nanostructures in Lymphoma

George J. Weiner, MD
Implementation of CARTs in Lymphoid Malignancies

Wing C. (John) Chan, MD
Molecular Targets in T-Cell Lymphoma

David L. Porter, MD
CAR-T Cells in Lymphomas: Rationale and Current Progress

Carlo M. Croce, MD
Targeting Micro RNA’s in Lymphoma

Andrew D. Zelenetz, MD, PhD
Patients with Mantle Cell Lymphoma should Receive an Autologous Stem Cell Transplant in First Remission (CON)

Koen van Besien, MD, PhD
Patients with Mantle Cell Lymphoma should Receive an Autologous Stem Cell Transplant in First Remission (PRO)

Michael R. Bishop, MD
Patients with Relapsed DLBCL Should Receive an Autologous not an Allogeneic Stem Cell Transplant in the modern Era

John Kuruvilla, MD
Patients with Relapsed DLBCL Should Receive an Autologous not an Allogeneic Stem Cell Transplant in the modern Era

Bertrand Coiffier, MD, PhD
A Decade after R-CHOP: How should DLBCL be Treated?

Tara Henderson, MD, MPH
Survivorship of Lymphoid Malignancies for the Practitioner

Paul Rubenstein, MD
HIV-Associated Lymphomas in 2014: Spectrum of Disease and Treatment Approach

Sonali M. Smith, MD
MYC-Driven Lymphomas: Diagnostic Considerations and Management Options

10th International Chicago Lymphoma Symposium 2013

Georg Lenz, MD
Dissecting Diffuse Large B-Cell Lymphoma: Why Does It Matter?

Adam Bagg, MD
The Genetics of Lymphoma

Laura Pasqualucci, MD
The Biology of B Cell Transformation

Adam M. Petrich, MD
PI3K/Akt/mTOR Inhibitors in Lymphoma: Predicting Response and Outcome

H. Miles Prince, MD, MBBS
Integrating Novel Therapies into the Management of Cutaneous T Cell Lymphomas

Oliver W. Press, MD, PhD
Emerging Immunotherapies for the Treatment of B Cell Malignancies

Michael E. Williams, MD, ScM
Non-Transplant Options in Mantle Cell Lymphoma: Who, When and Why?

Jane N. Winter, MD
Primary Mediastinal B-Cell Lymphoma

James Rubenstein, MD, PhD
Update on CNS Lymphomas: Primary CNS Lymphoma, Intraocular Lymphoma & Leptomeningeal Lymphoma

Bruce D. Cheson, MD
State of the Art: Staging, Restaging and Response Evaluation in Lymphomas

Sonali M. Smith, MD
Challenging Cases in Lymphoma

Andrew M. Evens. DO, MSc
Optimal Front-Line Treatment of Follicular Lymphoma

Timothy S. Fenske, MD
Timing of Hematopoietic Cell Transplantation (HCT) in Follicular Lymphoma

9th International Chicago Lymphoma Symposium 2012

Brian Chiu, PhD
The epidemiology of lymphoma: lessons learned

Susan Bates, MD
Epigenetics of lymphomas: the basics and the next steps

Jonathan Friedberg, MD, MMSc
BCR signaling in lymphoma: relevance and optimal targeting

Myron Czuczman, MD 
The microenvironment in lymphoma: is it druggable?

Richard Longnecker, PhD
The biology and pathogenesis of EBV-related lymphomas

Randy D. Gascoyne, MD, FRCPC
Prognostic markers in DLBCL: what is the current standard of care?

Brian Link, MDChristopher Flowers, MD, MS
Is watch and wait still an appropriate strategy in follicular lymphoma?

Andrew Evens, DO, MSc; Leo Gordon, MD; Scott Smith, MD, PhD; Chadi Nabhan, MD, FACP
PTLD and Burkitt’s lymphoma

Patrick J. Stiff, MDKoen Van Besien, MD 
High risk patients with DLBCL should undergo a stem cell transplant as part of front-line treatment

Volker Diehl, MD, PhD
Hodgkin lymphoma: historical perspective and future

Richard Ambinder, MD, PhD
EBV-related Lymphomas: Prognostic and Therapeutic Implications

Ranjana Advani, MD 
Current front-line approach to PTCL

Sonali Smith, MD
Autologous vs. allogeneic stem cell transplant in PTCL

8th International Chicago Lymphoma Symposium 2011

Jim Armitage, MD
Treatment of Follicular Lymphoma: The Role of Transplantation in the Post-Rituximab Era

Koen Van Besien, MD
Standard Therapy for Younger Patients with Mantle-Cell Lymphoma Should Include Stem Cell Transplantation. Pro vs. Con

James Bradner, MD, MSc
Utilizing Chemical Biology to Improve Targeted Therapies in Lymphoma

Elias Campo, MD, PhD
Integrating Molecular Insights into Future Treatments for Mantle Cell Lymphoma

Bouthaina S. Dabaja, MD
Radiotherapy should be standard therapy for primary mediastinal DLBCL Pro vs. Con

Andrew Evens, DO, MS
The Biology and Treatment of Elderly Hodgkin Disease

John Gribben, MD
Importance of Immunity and the Microenvironment in Follicular Lymphoma

Paul A. Hamlin, MD
Evaluation and Treatment of Very Elderly DLBCL

John P. Leonard, MD
Standard Therapy for Younger Patients with Mantle-Cell Lymphoma Should Include Stem Cell Transplantation. Pro vs. Con

Shuo Ma, MD, PhD
The Prognosis and Treatment of Elderly CLL

Christiane Pott, MD 
Minimal Residual Disease in MCL and FL: How, Who, and When?

John M. Pagel, MD, PhD
Application of Immunoconjugates in Non-Hodgkin Lymphoma

Sonali M. Smith, MD
Case Presentation & Discussions

George J. Weiner, MD
Increasing the Efficacy of Monoclonal Antibodies

Wyndham H. Wilson, MD, PhD, NIH, NCI
Radiotherapy should be standard therapy for primary mediastinal DLBCL Pro vs. Con

7th International Chicago Lymphoma Symposium 2010

John Anastasi, MD
Grey-Zone Lymphomas

Stephen Ansell, MD, PhD
The Future of Monoclonal Antibodies in Lymphoma: What’s Next?

Steven Bernstein, MD
CNS Prophylaxis: Who and How?

Amy Chadburn, MD
Viral Etiology of Lymphoma

Sandeep S. Dave, MD
MiRNA in NHL

Andrew Evens, DO, MS
Northwestern University

Leo I. Gordon, MD
Purine Analogs in Indolent Lymphoma: Pro Vs. Con

Steve Horwitz, MD
How I Treat: Systemic T-NHL

Brad Kahl, MD
Management of Very High Risk DLBCL: Is There Still a Role for Front-Line Transplant

Peter McLaughlin, MD
Purine Analogs in Indolent Lymphoma: Pro Vs. Con

Ari Melnick, MD
Targeting The Germinal Center: Why and How?

Scott Smith, MD
Management of Very High Risk DLBCL: Is There Still a Role for Front-Line Transplant

Sonali Smith, MD
PI3K/Akt/Mtor Pathway in Lymphoma: Progress Report and Future Outlook

Philippe Solal-Celigny, MD, PhD
Keynote Lecture: Prognosis in Follicular Lymphoma in the Modern Era

Joseph Sparano, MD
HIV and NHL in 2010: State of the Art Approach To Front-Line and Relapsed Disease

Koen van Besien, MD 
University of Chicago

Denis Weisenberger, MD
T-NHL: Biology and Prognostic Factors

6th International Chicago Lymphoma Symposium 2009

James Cerhan, MD
Genetic Epidemiology: Implications for the Clinical Practitioner

Ken Cohen, MD
NHL microenvironment

Michael Crump, MD
Cure, Late Effects and Prevention in Hodgkin Lymphoma

Andrew Evens, DO, MS
Rational Pathways to Target in Hodgkin lymphoma

Eric Hsi, MD
Biologic predictors and implications on treatment in follicular lymphoma

Neil Kay, MD
Novel approaches and agents for the treatment of relapsed/refractory CLL

Susan O’Brien, MD
Treatment Options for Newly Diagnosed CLL

Michael Pfreundschuh, MD
Perspectives on Front-line DLBCL–Current Status and the Future

Jorge Romaguera, MD
Treatment of mantle cell lymphoma:  is upfront aggressive chemotherapy and/or transplant needed?

Mathias Rummel, MD
Pro-Con: Is there a role for ASCT in follicular lymphoma?

Sonali Smith, MD
University of Chicago

Koen van Besien, MD
Pro-Con: Is there a role for ASCT in follicular lymphoma?

5th International Chicago Lymphoma Symposium 2008

Andreas Rosenwald
Biology and Prognosis of High Grade Lymphomas

Sonali Smith 
Treatment options for relapsed DLCL

John Sweetenham 
Treatment of High Grade Lymphomas

John Leonard 
New Monoclonal Antibodies in NHL

John Byrd  
CLL: Integration of Biology and Therapeutic Options

Andrew Evens
Challenging Cases: Elderly Hodgkin Disease and Lymphoma with Hepatitis

Julie Vose 
Transformed Lymphoma: Definition, Prognosis, and Treatment

Nancy Lee Harris 
Pathology and Classification of Follicular Lymphoma: WHO 2008

Thomas Witzig
Sequencing of Therapies in Follicular Lymphoma

Jane Winter 
Vaccine Therapy in Lymphoma: Current State of the Art

4th International Chicago Lymphoma Symposium 2007

Izidore Lossos
Gene Array and Diffuse Large B-Cell Lymphoma

Stephanie Gregory
Localized Diffuse Large B-Cell

Leo I. Gordon
Diffuse Large B-Cell Lymphoma

Lauren Abrey
Primary CNS Lymphoma—The Standard of Care

Koen Van Besien
Secondary CNS Lymphoma: Prevention and Treatment

Sonali M. Smith
Challenging Cases: Relapsed T-cell Lymphoma

Finbarr Cotter
Genetics of Mantle Cell Lymphoma: Clinical Implications

Patrick Stiff
Mantle Cell Lymphoma: Role of Stem Cell Transplantation

Martin Dreyling
Mantle Cell Lymphoma—The Next Steps

Lois Travis
Second Cancers Following Hodgkin Lymphoma

Andrew M. Evens
Hodgkin Lymphoma: Advance Stage Disease

3rd International Chicago Lymphoma Symposium 2005

Joachim Yahalom
Evolving Role of RT in Hodgkin’s Lymphoma

Madeleine Kraus
Pathology of Hodgkin’s Lymphoma

Volker Diehl
Treatment of Advanced Hodgkin’s Lymphoma

Joseph M. Connors
Nodular Lymphocyte Predominant Hodgkin’s Lymphoma

Steven T. Rosen
Non Cutaneous T-Cell Lymphoma

Andrew Evens
Challending Cases: Hodgkin Disease with Bulky Disease and Anaplastic T-cell Lymphoma

Koen van Besien
Allogeneic Transplant for Low Grade Lymphoma

Sonali M. Smith
Management of Relapsed Diffuse Large B-Cell Lymphoma

Leo Gordon
Radioimmunotherapy for Low Grade and Aggressive Lymphoma

2nd International Chicago Lymphoma Symposium 2003

John Anastasi
Overview on Biology and Classification of Large Cell Lymphoma

Jane N. Winter
Novel Prognostic factors in Large Cell Lymphoma

Sigrid Stroobants
The Use of PET Scanning in Diagnosis and Management of Large Cell Lymphoma

Julie Vose
Monoclonal Antibodies in Aggressive Lymphomas

Wyndham Wilson
The Role of Dose Intensity in Large Cell Lymphoma

Koen van Besien
High Dose Chemotherapy in Large Cell Lymphoma

Emanuele Zucca
Biology and Treatment of Localized MALT Lymphoma

Sonali M. Smith
Management of Disseminated Marginal Zone Lymphoma